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Abstract Breakthrough pain (BTP) is a transitory pain (reaching maximum severity
in ~15 minutes and lasting ~60 minutes in patients with cancer) that occurs
despite the management of chronic pain with long-term around-the-clock
analgesia. BTP occurs in 33–65% of patients with chronic cancer pain and in
~70% of patients with chronic noncancer pain. BTP has historically been
managed with short-acting opioids; however, these medications have a
pharmacokinetic profile that does not correlate with the sudden onset and
short time to maximum severity of BTP. Interest in rapid-onset opioids to
relieve BTP has therefore been growing. This comprehensive review aims to
summarize the currently available clinical data for the approved rapid-onset
opioids, which comprise different formulations of fentanyl, a m-opioid recep-
tor agonist with anaesthetic and analgesic properties. Administration routes
for fentanyl in the management of BTP currently include the transmucosal
and intranasal routes; an intrapulmonary formulation is also in development.
The findings of this review suggest that the efficacy and safety of the ap-
proved rapid-onset opioids are comparable.
1. Introduction
Breakthrough pain (BTP) is a transitory pain
that occurs despite the use of long-term, around-the-
clock analgesia to control chronic pain.[1] Three
types of BTP have been classified: spontaneous/
idiopathic, incident and end-of-dose failure BTP
(figure 1). BTPmay be nociceptive (localized pain
due to injury outside the nervous system), neu-
ropathic (pain caused by damage to the central or
peripheral nervous system) or a mixture of the
two pain types.[2]
BTP is highly prevalent in certain patient pop-
ulations, occurring in 33–65% of patients with
chronic cancer pain[3,4] and ~70% of patients with
chronic noncancer pain.[5] In patients with cancer,
the median time from BTP onset to maximum
intensity is 15 minutes and the median duration
of BTP in these patients is ~60 minutes.[6] In
patients with noncancer pain, peak pain intensity
reportedly occurs within 10 minutes of onset and
episodes can last for up to 1 hour.[5] BTP is fre-
quently detrimental to quality of life. In a study
of 43 patients with chronic noncancer pain and
BTP, 93% of patients reported that BTP had a
substantial effect on their general activity level
and ability to work, and 86% of patients stated
that it affected their enjoyment of life.[7] Despite
the impact of BTP, this condition is currently
under-recognized and under-treated.[8,9] Only
55% of patients take medication every time they
experience BTP even though 60% of all patients
with BTP describe it as a severe pain.[6]
Oral morphine and other traditional short-
acting opioids have traditionally been the back-
bone of both chronic pain and pharmacological
BTP management; however, the pharmacokinetic
profile of these agents – slow onset of analgesia
(time to achieve maximal plasma concentration
[tmax] for normal-release morphine is 1.1 hours
and onset of analgesia ~30 minutes), long half-life
(t½; 2 hours for oral morphine), extensive first-
pass metabolism and poor bioavailability (20–
40%) – does not correlate with the sudden onset
and short time to maximum severity of BTP.[10-13]
The need for more rapid pain relief in BTP has led
to growing interest in the use of rapid-onset opi-
oids (ROOs) for use in this setting. The first ROO
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indicated for BTP in opioid-tolerant patients with
cancer was oral transmucosal fentanyl citrate
(OTFC), a lozenge containing fentanyl citrate
incorporated into a dissolvable sugar-based ma-
trix. Since the approval of OTFC, several other
formulations and delivery routes have been de-
veloped for this indication (figure 2).
Clinical studies evaluating pain often focus on
statistically significant improvements, but greater
emphasis is increasingly being placed on clinically
meaningful changes in efficacy assessments. A study
of 130 patients with cancer-related BTP who
were undergoing titration to an efficacious dose
of OTFC revealed that a clinically important
improvement in pain intensity difference (PID)
could be defined as a decrease of >33% from base-
line within 30 minutes of administration.[14] Other
measures of clinically important improvements in
pain were a ‡2-point reduction in absolute pain
intensity (on an 11-point numeric scale where
0 = no pain and 10 =worst pain imaginable), pain
relief scores of ‡2 (on a 5-point categorical scale
where 0 = no pain relief and 4 = complete pain
relief) and a global medication performance score
of ‡2 (on a 5-point categorical scale where 0 =
poor and 4 = excellent).[14] In addition, 33% and
50% improvements in pain intensity scores have
been judged to be of moderate and substantial
clinical importance, respectively, in a recent con-
sensus statement on meaningful outcomes in clini-
cal studies of medications for chronic pain.[15]
This review evaluates current and future phar-
macological methods of alleviating BTP. The phar-
macokinetics of available formulations will be
explored as well as their efficacy and safety profiles
compared with placebo and with other opioids,
with inclusion of data on clinically meaningful re-
sponses in patients with chronic cancer or non-
cancer pain and BTP where available.
1.1 Search Strategy and Selection Criteria
A MEDLINE search was conducted on Sep-
tember 20, 2011 using the following search terms:
‘rapid onset opioids’ OR ‘rapid acting opioids’




Unpredictable BTP without a
readily identifiable cause
>50% of BTP is reported to be
spontaneous[2]
Incident
Induced by specific activities
such as coughing or walking
End-of-dose failure
Associated with declining serum
concentrations of around-the-clock
analgesic medication used for
persistent pain
Has a more gradual onset and
prolonged duration than other
breakthrough episodes
Fig. 1. Categorization of breakthrough pain (BTP).
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AND (‘Administration, Buccal’[Mesh] OR
‘Administration, Sublingual’[Mesh] OR ‘Admin-
istration, Oral’[Mesh] OR ‘Administration,
Intranasal’[Mesh] OR ‘Administration, Intra-
pulmonary’[Mesh]); ‘Fentanyl’[Mesh] AND
‘Pharmacokinetics’[Mesh]; ‘Fentanyl’[Mesh] AND
(‘Patient Satisfaction’[Mesh] OR ‘Patient Pref-
erence’[Mesh]).
Papers were limited to those written in English
that were concerned with human subjects. Date
limits were January 1, 2000 to September 20, 2011.
Additional articles were identified by searching
the reference lists of included papers.
Papers were included in this review if they re-
ported on BTP in patients with chronic cancer
or noncancer pain and included information on
pharmacokinetics, efficacy or safety. Papers were
excluded if they concerned transdermal fentanyl
(indicated for the treatment of chronic pain), treat-
ment of chronic pain, case studies, postoperative
or labour pain, oral forms of opioids (i.e. opioids
that are not rapid onset) or were reviews of BTP
in general. For papers detailing efficacy, priority
was given to reporting the findings from ran-
domized controlled trials.
A summary of the randomized clinical studies
is given in table I; this table includes both study
design and Jadad scale scores in order that the
reader may draw conclusions as to the methodo-
logical quality of the studies. Jadad scale scores
range from 0 (very poor methodological quality)
to 5 (rigorous methodological quality).[33]
2. Administration Routes for Breakthrough
Pain (BTP)
Route of administration is an important con-
sideration in the treatment of a fast-onset condition
such as BTP, as it can affect the rate of dissolu-
tion and absorption and consequently can affect
the bioavailability of a drug. Table II summarizes
the different routes used to administer opioid
medications for treating BTP. The choice of ad-
ministration route for ROOs is heavily dependent
on individual patient characteristics, including
their clinical stability in terms of their underlying
disease, likely adherence to medication regimens,
the characteristics of their BTP (onset, predict-
ability, severity and duration) and formulation
preferences. For example, some patients may
find it difficult or uncomfortable to use a med-
ication that requires inhalation, while individuals
with severe dysphagia may prefer not to use oral
formulations.
Patients may express preference for certain
administration routes for BTP medications. In a
questionnaire study of 100 patients with cancer
pain, 97%, 50%, 63% and 44% of patients re-
ported that they would find it acceptable to take




































1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Fig. 2. Timeline of rapid-onset opioid approval in the US and EU. EMA =European Medicines Agency; FBSF = fentanyl buccal soluble film;
FBT = fentanyl buccal tablet; FPNS = fentanyl pectin nasal spray; INFS = intranasal fentanyl spray; OTFC = oral transmucosal fentanyl citrate;
SLF = sublingual fentanyl.
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mild/moderate BTP, respectively; for severe BTP
the rates were 88%, 68%, 75% and 63%, respect-
ively.[35] All of the patients were familiar with
using oral medications and the small proportion
of respondents who stated that such medication
would be unacceptable for BTP gave ‘‘slow onset
of analgesia’’ as their reason. By contrast, only
2% of respondents had previous experience of
using buccal medications (the OTFC lozenge on a
stick) and perhaps unsurprisingly gave unfamili-
arity as a major motive for finding this treatment
modality unacceptable. In addition, respondents
reported concerns regarding the potential for an
unpleasant taste/nausea and the childish appear-
ance of buccal medications. Worries regarding
the fear of an unpleasant taste/nausea were also
given as reasons for the unacceptability of nasal
and inhaled medications for BTP. Previous bad
experiences with sublingual and inhaled medica-
tions were further motives for rejection.[35] Pa-
tients with pain/disease in the area where a drug
would be administered, e.g. due to cancer of the
head and neck, responded that they would find
nasal or inhaled drug administration unacceptable
due to the nature of their illness. The acceptability
rates and reasons given by respondents highlight
the necessity for individualization of treatment
for patients with chronic pain and BTP.
3. Current Treatments for BTP
At present the only rapid-onset analgesic that
is suitable for the treatment of BTP is fentanyl,
a m-opioid receptor agonist with anaesthetic and
analgesic properties. It is highly lipophilic, so it
diffuses quickly across the blood-brain barrier.[37]
The pharmacokinetics of fentanyl makes it par-
ticularly suitable for the treatment of BTP. For
example, fentanyl has an equilibration t½ of 6 min-
utes compared with 2–3 hours for morphine.[11]
This means that fentanyl produces rapid analge-
sia that appears to closely match the time course
of many episodes of BTP.[13] Fentanyl is primar-
ily metabolized by cytochrome P450 (CYP) 3A4
and concomitant use with inhibitors of this en-
zyme can lead to increased fentanyl levels and an
increased risk of respiratory depression. Patients
taking fentanyl with CYP3A4 inhibitors should
be monitored closely and dosage increases should
be carried out conservatively. Moreover, fentanyl
should not be administered to patients who have
taken monoamine oxidase inhibitors within the
previous 14 days[38,39] or patients who are opioid
non-tolerant.[40] As with all opioid analgesics,
fentanyl overdose may result in respiratory fail-
ure due to severe hypoventilation.[41,42]
Only limited data are available on the re-
lationship between the total daily dose of a fixed-
schedule opioid regimen and the dose of opioid
required to manage BTP. In a preliminary study
in 12 patients with cancer-related BTP, fentanyl
buccal tablet (FBT) in doses proportional to the
high doses of opioids used for background an-
algesia was efficacious.[43] However, it should be
noted that doses of fentanyl that prove effica-
cious with one formulation may not demonstrate
the same efficacy and tolerability when adminis-
tered by another route.[29] Thus, different fenta-
nyl formulations require individually titrated
regimens based on patient response.[44] Studies of
fentanyl usually include a dose-titration phase so
that individual patients can identify the dose of
the formulation that provides them with the best
balance of efficacy and tolerability.
Of note, fentanyl formulations are currently
only indicated for the management of BTP in
opioid-tolerant patients with cancer, and are
not recommended for the management of BTP in
patients with pain of non-cancer origin. Use of
these agents in patients with non-cancer pain is
currently off label and is not supported by cur-
rent literature. Key concerns with the use of
fentanyl in patients with conditions other than
cancer are those of abuse and addiction,[45] and
potential fatalities in patients who are not opioid
tolerant. Despite these concerns, the off-label use
of fentanyl preparations is widespread. In 2007, a
study observed that nearly 90% of OTFC pre-
scriptions were off label, or not prescribed ac-
cording to the FDA guidelines.[46] Off-label use
may contribute to the fatalities that are observed
with these products. For example, during the period
January 2004 to June 2011, 55 deaths occurred
in which OTFC was considered to be the pri-
mary suspect.[47] In recognition of concerns about
misuse, abuse, addiction, overdose and serious
Rapid-Onset Opioids for Breakthrough Pain 515
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complications due to medication errors, a risk
evaluation and mitigation strategy for all trans-
mucosal immediate-release fentanyl formulations
was introduced in December 2011.[48]
3.1 Oral Transmucosal Fentanyl Citrate
OTFC (Actiq) is a sweetened lozenge con-
taining fentanyl citrate that is attached to a stick
to help the patient sweep the medication across
the buccal mucosa (lining of the cheek). Admin-
istration of the lozenge takes ~15 minutes.[49]
OTFC was developed by Anesta Corp. (later
acquired by Cephalon, Inc.) and was approved in
the US in 1998 for BTP in adults with cancer who
are receiving, and are tolerant of, opioid analge-
sics for underlying chronic cancer pain. OTFC
was approved in Europe for the same indication
in 2002. OTFC is available in six dose strengths:
200, 400, 600, 800, 1200 and 1600 mg.
The sugar content of the OTFC lozenge im-
proves its palatability for patients but some con-
cerns have been raised regarding dental problems
with prolonged and repeated use.[50] Furthermore,
self-administration of medication for BTP may be
seen as a burden for chronically ill patients; con-
sequently, formulations developed after OTFC
tended to focus on ease of administration/lack of
active participation on the part of the patient.[50]
3.1.1 Pharmacokinetics
When the OTFC lozenge is administered as
directed, 25% of the total dose of fentanyl is ab-
sorbed by the buccal mucosa and becomes sys-
temically available. Approximately 75% of the
OTFC dose is swallowed and is then absorbed
from the gastrointestinal tract where two-thirds is
eliminated via first-pass metabolism.[51] The bio-
availability of OTFC is therefore ~50% of the
total dose, split evenly between transmucosal and
(slower) gastrointestinal absorption.[51] This re-
latively lower bioavailability among ROOs does
not appear to significantly affect the clinical effi-
cacy and safety profiles of OTFC as these are
comparable to those of other available agents. In
a multiple-dose pharmacokinetic study in healthy
volunteers (800 mg for three consecutive doses),
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40% with central and peripheral distributions of
17L and 26L, respectively.[52] Multiple doses of
OTFC did not result in a pharmacokinetic profile
that was substantially different to that observed
after single-dose administration.[52] Summary
pharmacokinetic data for OTFC are detailed in
table III.
OTFC has demonstrated dose proportionality
at 200, 400, 800 and 1600 mg, as increasing doses
result in increasing serum levels of fentanyl. The
median tmax for these four doses ranged from
40 minutes to 20 minutes, the mean maximal
plasma concentration (Cmax) ranged from0.4ng/mL
to 2.5 ng/mL and the mean t½ ranged from
3.2 hours to 6.4 hours (for the 200 mg and 800 mg
doses, respectively).[53]
3.1.2 Clinical Efficacy versus Placebo
The efficacy of OTFC has been compared with
placebo in a multicentre, double-blind, random-
Table III. Summary pharmacokinetic dataa for fentanyl formulations
Formulation and dose (mg) tmax mean (median), min Cmax mean, ng/mL t½ mean (median), h Bioavailability,% References
OTFC
200 (40) 0.4 3.2
400 (25) 0.8 6.4 40–50 51,53
800 (25) 1.6 6.4
1600 (20) 2.5 6.0
FBT
100 (45) 0.3 (2.6)
200 (40) 0.4 (4.4)
400 (35) 1.0 (11.1)
600 (78) 1.4 16.0 65 54,55
800 (40) 1.6 (11.7)
1000 (84) 2.0 18.1
1200 (96) 2.3 18.8
1300 (60) 2.8 20.1
FBSF
600 60–120 1.0–1.1 9.8–12.7 71 56
800 90 1.3 19.0
SLF
100 40 0.2 6.1
200 49 0.4 6.3 NA 57
400 57 0.9 5.4
INFS
50 23 (15) 0.4 3.2
100 24 (12) 0.6 4.3 89 58,59
200 13 (15) 1.2 3.5
FPNS
100 20 0.4 21.9
200 15 0.8 24.9 NA 60
400 21 1.6 15.0
800 20 2.8 24.9
a Results are from different studies in healthy volunteers and patients with chronic pain and therefore are not directly comparable.
Cmax =maximal plasma concentration; FBSF = fentanyl buccal soluble film; FBT = fentanyl buccal soluble tablet; FPNS = fentanyl pectin nasal
spray; INFS = intranasal fentanyl spray; NA= not available; OTFC =oral transmucosal fentanyl citrate; SLF = sublingual fentanyl; t½ =half-life;
tmax = time taken to achieve maximal plasma concentration.
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ized study of opioid-tolerant patients with cancer
and BTP (table I).[16] Compared with BTP episodes
in patients administered placebo, PID scores for
episodes in those treated with OTFC were sig-
nificantly greater from 15 minutes to 1 hour after
administration (p < 0.0001).[16] Significant differ-
ences between OTFC and placebo were also evi-
dent in terms of global performance (mean scores
1.98 and 1.19 for OTFC and placebo, respect-
ively; p< 0.0001) and use of rescue medications
(supplementary medication taken in addition to
the initial dose of opioid for BTP; 15% vs 34% of
episodes; p < 0.0001).
3.1.3 Clinical Efficacy versus Other Opioids
OTFC has been compared with morphine ad-
ministered by a variety of routes. The efficacy of
OTFC was compared with that of intravenous
morphine in a study of 25 opioid-tolerant patients
with cancer and BTP.[18] Pain intensity decreased
by 41.4% and 51.7% in the first 15 minutes after
dosing with OTFC and intravenous morphine,
respectively (p= 0.026 for treatment comparison).
At 30 minutes, the reduction in pain intensity was
65.9% and 73.8%, respectively (p= 0.136 for treat-
ment comparison).[18] Although the intravenous
route provided rapid and effective pain relief,
OTFC conferred the advantage of ease of use;
self-administration of parenteral morphine is
unlikely to be practical for the day-to-day man-
agement of BTP.[18]
In a randomized, double-blind, crossover study
of opioid-tolerant patients with cancer that com-
pared OTFC with immediate-release oral morphine
sulphate (table I), the buccal lozenge was signif-
icantly more effective across all time points when
assessed by reductions in pain intensity (p£ 0.033),
mean PID (p < 0.008), pain relief (p £ 0.009) and
global performance rating (p£ 0.001). Furthermore,
a significantly greater proportion of BTP episodes
treated with OTFC demonstrated a clinically sig-
nificant ‡33% change in pain intensity at 15 min-
utes compared with immediate-release morphine
sulphate (table IV).[17] Rescue medication due to
perceived treatment failure was required in a
similar proportion of BTP episodes treated with
OTFC or oral morphine (2% and 1%, respectively;
p= 0.5385).[17]
3.1.4 Safety and Tolerability
Across the clinical studies of OTFC, reported
adverse effects were typical of opioids and in-
cluded somnolence, nausea and dizziness.[16,44,61]
Hallucinations and confusion relating to the use
of OTFC have also been reported in clinical
studies of this formulation.[17]
Both the OTFC lozenge and a compressed pow-
der formulation of OTFC were easily tolerated by
patients with radiation-induced oral mucositis
(ulceration of the oral mucous membranes). OTFC
has therefore been suggested as a useful treatment
for pain in patients with severe oral mucositis,[62]
although it is possible that some patients may find it
difficult to produce enough saliva for dissolution.
3.1.5 Patient Satisfaction/Preference and
Quality of Life
In an open-label, long-term safety study, OTFC
(200–1600 mg) was used to treat 38 595 episodes of
BTP in 155 opioid-tolerant patients with cancer.
These patients consistently gave global satisfac-
tion ratings above 3 (where 0 = poor and 4=
excellent), indicating that the pain relief provided
by OTFC was very good or excellent.[63] In a small
study (n = 14) of OTFC formulated as either a
sweetened matrix or a compressed powder in
patients with radiation-induced oral mucositis,
50% of patients preferred the sweetened matrix
compared with 21% for the powder (p = 0.343).
This numeric difference in preference ratings may
be due to the occurrence of a burning sensation in
the mouth reported by more patients during ad-
ministration of the powder than the sweetened
matrix (10 patients vs 4 patients).[62]
OTFC has been reported to improve quality of
life in patients with noncancer pain and BTP. In a
study of 43 patients (mostly with chronic back
pain), 65% reported that OTFC improved their
enjoyment of life by ‘‘quite a bit’’ or ‘‘very much’’,
and 61% and 58% reported that OTFC improved
their mood and their general activity level by
‘‘quite a bit’’ or ‘‘very much’’, respectively.[7] In
the same study, patients reported a statistically
significantly greater preference for OTFC versus
their previous BTP medication (hydrocodone,
acetaminophen [paracetamol], oxycodone or a
combination) in terms of satisfaction (p < 0.001),
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Table IV. Clinically meaningful improvements with fentanyl vs comparators (placebo or other opioids)
Reference Study design and fentanyl
formulation
Moderate (‡33%) clinically relevant
improvement in pain intensity
(% episodes)
Substantial (‡50%) clinically relevant
improvement in pain intensity
(% episodes)
Active control
Coluzzi et al.[17] OTFC vsMSIR in 93 opioid-tolerant
patients with chronic cancer pain









INFS vs OTFC in 139 opioid-
tolerant patients with chronic
cancer pain and BTP; open-label,
randomized study
At 5min:
INFS = 25%, OTFC = 7% (p < 0.001)
At 10min:
INFS = 51%, OTFC = 24% (p < 0.001)
At 5min:
INFS = 13%, OTFC =2% (p <0.001)
At 10min:
INFS = 37%, OTFC =10% (p <0.001)
Ashburn
et al.[24]
FBT vsOxyIR in 190 opioid-tolerant
patients with chronic cancer/




FBT =13%, OxyIR =9% (p < 0.05)
At 30min:
FBT =41%, OxyIR =32% (p < 0.05)
At 15min:
FBT =6%, OxyIR =4% (p =NS)
At 30min:




FBT vs placebo in 77 opioid-
tolerant patients with chronic
cancer pain and BTP; randomized,
double-blind study
At 15min:
FBT =13%, placebo =9% (p =0.045)
At 30min:
FBT =48%, placebo =29% (p <0.0001)
At 45min:
FBT =71%, placebo =44% (p <0.0001)
At 60min:
FBT =75%, placebo =48% (p <0.0001)
At 15min:
FBT =8%, placebo =6% (p =NS)
At 30min:
FBT =24%, placebo =16% (p <0.05)
At 45min:
FBT =51%, placebo =25% (p <0.0001)
At 60min:
FBT =64%, placebo =35% (p <0.0001)
Portenoy
et al.[20]
FBT vs placebo in 77 opioid-
tolerant patients with chronic low
back pain and BTP; randomized,
double-blind study
At 15min:
FBT =20%, placebo =11% (p <0.01)
At 30min:
FBT =42%, placebo =18% (p £0.0001)
At 60min:
FBT =58%, placebo =26% (p £0.0001)
At 2 h:
FBT =65%, placebo =28% (p £0.0001)
At 15min:
FBT =11%, placebo =5% (p =NS)
At 30min:
FBT =30%, placebo =13% (p £0.0001)
At 60min:
FBT =44%, placebo =15% (p £0.0001)
At 2 h:
FBT = 48%, placebo =16% (p £0.0001)
Simpson
et al.[21]
FBT vs placebo in 79 opioid-
tolerant patients with chronic
noncancer pain with BTP;
randomized, double-blind study
At 10min:
FBT =9%, placebo =3% (p =0.008)
At 15min:
FBT =23%, placebo =13% (p =0.006)
At 15min:
FBT =12%, placebo =5% (p =0.001)
Kress et al.[28] a INFS vs placebo in 111 opioid-
tolerant patients with chronic
cancer pain and BTP; double-blind,
randomized study
At 10min:
INFS = 58%, placebo = 28% (p< 0.001)
At 20min:
INFS = 80%, placebo = 44% (p< 0.001)
At 40min:
INFS = 86%, placebo = 48% (p< 0.001)
At 60min:
INFS = 87%, placebo = 49% (p< 0.001)
At 10min:
INFS = 37%, placebo = 14% (p< 0.001)
At 20min:
INFS = 60%, placebo = 28% (p< 0.001)
At 40min:
INFS = 69%, placebo = 33% (p< 0.001)
At 60min:
INFS = 73%, placebo = 38% (p< 0.001)
Slatkin et al.[22] FBT vs placebo in 86 opioid-
tolerant patients with chronic
cancer pain and BTP; double-blind,
randomized study
At 10min:
FBT =16%, placebo =10% (p =0.007)
At 15min:
FBT =29%, placebo =14% (p <0.0001)
At 30min:
FBT =51%, placebo =26% (p <0.0001)
At 10min:
FBT =7%, placebo =4% (p =0.033)
At 15min:
FBT =18%, placebp =8% (p <0.0001)
At 30min:
FBT =38%, placebo =15% (p <0.0001)
Continued next page
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pain relief that allows a return to sleep (p < 0.001),
ease of use (p< 0.05), rapid onset of effect (p< 0.001),
adequate pain relief (p< 0.001), ease of understand-
ing (p< 0.001) and perception of safety (p< 0.001).
The only domain that did not reach statistical
significance was that of comfort with taking in
public.[7]
3.2 Fentanyl Buccal Tablet
The FBT Fentora was developed by Cepha-
lon Inc. It was approved in the US in 2006 for
BTP in adults with cancer pain who are receiving
and are tolerant of opioid analgesics for under-
lying chronic cancer pain. FBT was approved for
the same indication in the EU in 2008 under
the brand name Effentora. FBT is available in
doses of 100, 200, 400, 600 and 800 mg. FBT uses
OraVescent delivery technology to alter the pH
of the oral environment in order to assist with
dissolution and maximize absorption of fentanyl.
Dissolution takes 14–25 minutes with FBT and
does not require active participation from the
patient.[64] The OraVescent system produces an
effervescence reaction that releases carbon diox-
ide to produce carbonic acid in the buccal cavity.
The resultant decrease in pH optimizes tablet
dissolution. FBT then releases sodium carbonate
to raise the pH in order to increase permeation of
fentanyl through the buccal mucosa.[65,66] The
buccal pH changes orchestrated by this efferves-
cence reaction result in a greater proportion of
fentanyl being absorbed transmucosally instead
of being swallowed and absorbed by the slower
gastrointestinal route. Because 50% of the fenta-
nyl in FBT is absorbed transmucosally,[54] CYP
metabolism is bypassed to a greater extent than
with traditional short-acting opioids and OTFC,
so a greater proportion of fentanyl enters the
systemic circulation.[67] The time taken for FBT
to dissolve in the mouth (‘‘dwell time’’) does not
affect the rate and extent of fentanyl absorption
through the buccal mucosa.[68]
3.2.1 Pharmacokinetics
Summary pharmacokinetic data for FBT are
detailed in table III. In a study of 39 healthy
volunteers that evaluated the single-dose pharm-
acokinetics of FBT (270–1300 mg), mean t½ val-
ues ranged from 6.6 hours to 13.2 hours.[67] The
tmax values were comparable for doses ranging
from 270 mg to 1080 mg (median 54–72 minutes),
although tmax was longer after administration of
FBT 1300mg (90 minutes). Cmax increased in a less
than dose proportional manner at doses higher
than 810 mg; however, this was offset by a sus-
tained peak serum fentanyl concentration with
higher FBT doses so that total systemic exposure
was dose proportional across the full range of
doses assessed. Dose proportionality has also been
Table IV. Contd
Reference Study design and fentanyl
formulation
Moderate (‡33%) clinically relevant
improvement in pain intensity
(% episodes)
Substantial (‡50%) clinically relevant
improvement in pain intensity
(% episodes)
Farrar et al.[23] a FBT vs placebo in 91 opioid-
tolerant patients with chronic
noncancer pain and BTP; multiple
crossover study with 3 randomized,
double-blind phases over 12wk
At 5min:
FBT =7%, placebo =3% (p =0.0150)
At 15min:
FBT =26%, placebo =15% (p <0.05)
At 30min:
FBT =40%, placebo =26% (p £0.0001)
At 90min:
FBT =54%, placebo =31% (p £0.0001)
At 5min:
FBT =4%, placebo =2% (p =NS)
At 15min:
FBT =17%, placebo =10% (p =0.0216)
At 30min:
FBT =29%, placebo =15% (p =0.0005)
At 90min:
FBT =41%, placebo =23% (p £0.0001)
Rauck et al.[25] FBSF vs placebo in 82 opioid-
tolerant patients with chronic
cancer pain and BTP; randomized,
multiple crossover study
At 30min:
FBSF =47%, placebo = 38% (p = 0.009)
At 30min:
FBSF =33%, placebo =24% (p = 0.002)
a Values were read from graphs and are therefore approximate.
BTP =breakthrough pain; FBSF = fentanyl buccal soluble film; FBT = fentanyl buccal tablet; INFS = intranasal fentanyl spray;MSIR =morphine
sulphate immediate release; NS = not significant; OTFC =oral transmucosal fentanyl citrate; OxyIR =oxycodone immediate release.
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demonstrated for FBT over the 600-1300 mg
range in terms of mean Cmax and area under the
plasma concentration versus time curve from
time zero to infinity (AUC0–¥) [overall systemic
exposure].[69] The tmax values in this study ranged
from 1.0 hours for the 1300 mg dose to 1.6 hours
for the 1200 mg dose.[69] Dose proportionality in
terms of systemic exposure is important as it in-
dicates that stepped increases in FBT dose will
result in a proportionally increased circulating
fentanyl concentration. A predictable and linear
increase in systemic exposure can therefore be
expected with FBT titrated up to 1300 mg.[67,69]
Use of four 100 mg doses of FBT was reported
not to be bioequivalent to one 400 mg dose of
FBT, although differences in Cmax and AUC0–¥
were small (~10%).[70] The difference was attrib-
uted to the buccal mucosa coming in contact with
a larger surface area of tablet when four smaller
doses were used, thereby increasing absorption.[70]
Because fentanyl exposure with one 400 mg dose
of FBT was less than that with four doses of FBT
100 mg, patients can use the four single tablets to
titrate up to the 400 mg dose.
The bioavailability of FBT has been directly
compared with that of OTFC.[67] A lower dose of
FBT (1080 mg) provided comparable systemic ex-
posure to that of a higher dose of OTFC (1600mg)
[AUC0–¥ mean (SD): 18.0 (5.4) vs 18.0 (7.1) ng
h/mL for FBT 1080 mg and 1600 mg, respectively].
FBT had a tmax of 1.0 hours compared with 2.0
hours for OTFC (p < 0.001) and the AUC0–tmax
was 1.5 ngh/mL versus 0.8 ngh/mL (p< 0.001).
These results indicate that compared with the
fentanyl lozenge, FBT provided higher early sys-
temic exposure, which could result in the earlier
onset of pain relief,[67] although studies that di-
rectly compare the efficacy of OTFC with that of
FBT have not been performed.
In an additional study that directly compared
the pharmacokinetics of FBT 400 mg with those
of OTFC 800 mg, the median tmax was 47 minutes
and 91 minutes, respectively.[54] Furthermore, FBT
had greater absolute bioavailability compared
with OTFC (65% vs 47%). Approximately 48%
of the total fentanyl dose in FBT was absorbed
buccally compared with 22% for OTFC.[54] In
addition, dose normalization of OTFC to 400 mg
revealed greater earlier systemic exposure with
FBT compared with OTFC to the extent that
a 30% lower dose of FBT would result in com-
parable systemic exposure to that of the fentanyl
lozenge.[54]
Xerostomia (dry mouth due to a lack of saliva)
and oral mucositis are common issues in patients
with cancer. The absorption of FBT was com-
pared between patients with and without mild
oral mucositis (eight patients in each group).[71]
In this study, FBT dissolved within 30 minutes in
14 of 16 patients with or without oral mucositis
and tmax and Cmax were comparable in both
groups. Patients with oral mucositis did not ex-
perience exacerbations of their oral symptoms
during the study.
The sublingual area has greater salivary flow
than the buccal cavity and therefore sublingual
placement may be more comfortable for patients
and allowmore rapid absorption of transmucosal
preparations.[72] Bioequivalence has been dem-
onstrated between sublingual and buccal place-
ment of FBT in healthy volunteers meaning that
patients taking FBT have the option of using
either administration site without compromising
absorption.[73] These findings indicate that FBT
is a useful treatment option for patients with
cancer and BTP who have low levels of saliva or
oral problems.[71,73] FBT provides equivalent ab-
sorption in such patients as well as an alternative
site of administration so that particularly sore or
dry areas of the mouth can be avoided.
3.2.2 Clinical Efficacy versus Placebo
FBT has been shown to confer statistically and
clinically significant improvements in the treat-
ment of BTP in patients with cancer and non-
cancer pain in five placebo-controlled studies.[19-23]
The clinically relevant improvements in pain in-
tensity observed in these studies are summarized
in table IV. In brief, compared with placebo, FBT
demonstrated significant reductions in summed
PIDs over 60 minutes (SPID60) and PID from
10 minutes, significant increases in pain relief
from 10 minutes and moderate and substantial
clinically relevant improvements in pain intensity
from 5 and 15 minutes, respectively.[19-23] In ad-
dition, lower rates of rescue medication use and
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significantly greater medication performance as-
sessment scores were reported with FBT.[19-23]
3.2.3 Clinical Efficacy versus Other Opioids
The efficacy of FBT has been compared with
that of immediate-release oral oxycodone in a
recently reported randomized, double-blind cross-
over study of 190 opioid-tolerant patients with
chronic cancer or noncancer pain and BTP.[24]
As mentioned previously, compared with tradi-
tional short-acting opioids, ROOs have a phar-
macokinetic profile that more closely matches the
dynamics of BTP. The findings of this study
support this supposition as FBT treatment re-
sulted in statistically significantly greater PID
scores than immediate-release oxycodone within
5 minutes (p = 0.0081) and this significant dif-
ference was maintained through 60 minutes
(p < 0.0001). Pain relief was significantly better
with FBT versus immediate-release oxycodone at
10 minutes (p = 0.0275) through 60 minutes
(p < 0.05). The primary efficacy assessment of this
study was the mean PID at 15 minutes (PID15)
measured on an 11-point numeric scale. The
study results demonstrated that the mean PID15
was significantly greater with FBT compared
with oxycodone (0.82 vs 0.60; p < 0.0001). SPID60
and total pain relief at 60 minutes were also sig-
nificantly greater with FBT (p < 0.0001 for both),
indicating that FBT not only had a rapid onset of
effect but also maintained its analgesic effects
when compared with a traditional short-acting
opioid.[24] Patients stated that the 30-minute
post-dose medication performance of FBT was
‘‘good’’ to ‘‘excellent’’ in 41% of BTP episodes
compared with 26% of episodes treated with
oxycodone (p < 0.0001).[24]
3.2.4 Safety and Tolerability
No unexpected safety or tolerability concerns
have been noted with FBT. The most common
adverse events experienced with FBT are typical
of opioids, for example, nausea, dizziness and
vomiting, and decrease in incidence over time.[74]
Application-site abnormalities were reported by
5–15% of patients in clinical studies of FBT but
were predominantly transient and mild to mod-
erate in severity.[20-24,74,75]
3.2.5 Patient Satisfaction/Preference and
Quality of Life
Patients reported FBT to be preferable to tra-
ditional short-acting opioids in three studies.
When patients with noncancer pain and BTP
were queried about their medication preferences
in an open-label tolerability study of FBT, more
patients at all study visits (over an 18-month period)
reported that they preferred FBT to their previous
BTP medication (for example, oral morphine,
oxycodone or hydrocodone). Patients ascribed this
preference to the faster onset of action (94–97%
of patients), convenience (80–90% of patients)
and ease of administration (81–94% of patients)
of FBT compared with traditional short-acting
opioids.[75]
In a long-term, open-label study, patients with
chronic cancer pain stated a greater overall pref-
erence for FBT compared with their previous
BTPmedication (88% vs 12%).[74] Greater patient
satisfaction with FBT versus previous medica-
tions was also reported for time to onset of pain
relief (95% vs 5%), ease of administration (66%
vs 34%) and convenience of use (68% vs 32%).
Moreover, 93%, 82% and 80% of patients stated
that FBT was excellent/good for onset of action,
convenience of use and ease of administration,
respectively.[74]
In a study comparing FBT with immediate-
release oxycodone for BTP in patients with can-
cer or noncancer pain, 52% of patients stated a
preference for FBT compared with 33% for oxy-
codone; the remaining patients expressed no pref-
erence or did not complete the questionnaire.[24]
Patients were blinded to treatment in this ana-
lysis, so the results of this assessment were more
rigorous than reported when querying patients
about preferences in open-label studies.
In a 12-week, randomized, double-blind study
of FBT, improvements in all subscales of the Medi-
cal Outcomes Study Short-Form (36-item) Health
Survey were reported at the final study visit with
particular improvements in role limitations and
social functioning. Moreover, total scores and
anxiety also improved on the Profile of Mood
States.[23]
In a long-term, open-label safety study, opioid-
tolerant patients with chronic noncancer pain
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and BTP (n = 646) reported that FBT improved
their quality of life across a number of general-
ized scales. Of note, >65% of patients reported
that FBT lessened the interference of pain in their
enjoyment of daily life and it also improved their
general activity and sleep. In addition, 70–80% of
patients reported improvements in their ability to
work, socialize and enjoy life.[75]
3.3 Fentanyl Buccal Soluble Film
The fentanyl buccal soluble film (FBSF)
Onsolis was developed by Meda Pharmaceuti-
cals Inc. and utilizes BioErodible MucoAdhesive
(BEMA) technology (BioDelivery Sciences In-
ternational). It was approved in the US in 2009
for BTP in adults with cancer who are receiving
and who are tolerant of opioid analgesics for
chronic cancer pain. FBSF was approved in the
EU in 2010, where it is marketed as Breakyl for
the same indication. FBSF is available in doses of
200, 400, 600, 800 and 1200 mg per film.
FBSF presents fentanyl in a layer that adheres
to the inside of the patient’s cheek; an outer layer
isolates the fentanyl-containing layer from saliva.
In this way, the FBSF minimizes the quantity of
fentanyl that is swallowed in the saliva and that is
consequently lost during first-pass metabolism.[56]
The size of each FBSF is directly proportional to
the strength of the administered fentanyl dose.
FBSF does not require continuous patient partic-
ipation for effective administration (compared
with OTFC, which must be swept across the
buccal mucosa) and disintegrates completely in
the mouth.
3.3.1 Pharmacokinetics
Summary pharmacokinetic data for FBSF are
presented in table III. The pharmacokinetics of
FBSF 800 mg preparations at pH 6, 7.25 and 8.5
were compared with those of OTFC 800 mg in an
open-label, single-dose, crossover study in 12
healthy subjects in order to determine the pH that
allowed the most rapid dissolution with effec-
tive absorption.[76] Compared with OTFC, all
three FBSF formulations had higher Cmax values
(1.0ng/mL vs 1.4–1.7ng/mL; p= 0.03) and greater
overall systemic exposures (AUC0–¥ 10.3ngh/mL
vs 13.1–14.5 ngh/mL). tmax was 2.0 hours for
the pH 6 and pH 8.5 FBSF preparations and for
OTFC. tmax for the pH 7.25 FBSF was half that
of the other formulations assessed and this pre-
paration led to the greatest overall systemic ex-
posure (41% higher than OTFC) and Cmax (65%
higher than OTFC; p< 0.05). The pH 7.25 FBSF
was therefore selected for further evaluation in
the FBSF development programme.[76]
Overall mean plasma concentration was re-
producible after single doses of FBSF 600 mg and
the median tmax of this formulation was 1.0–2.0
hours in a study where healthy volunteers re-
ceived two doses of FBSF with a 3-day dosing
interval.[77]
A pharmacokinetics study that evaluated a
single 800 mg dose of FBSF compared with four
200 mg films taken simultaneously reported that
these two treatments were bioequivalent.[56]
Cmax, overall exposure (as measured by AUC0–¥)
and absolute bioavailability were the same for the
two dosing methods.[56] tmax occurred slightly
later when fentanyl was administered as four sep-
arate films (2.5 vs 1.5 hours for the 800 mg single
FBSF dose), although this difference did not
reach statistical significance (p = 0.078).[56] The
study authors stated that bioequivalence of the
two FBSF regimens occurred because the absorp-
tion of fentanyl was proportional to the surface
area of the film – the surface area of four 200 mg
films being identical to that of a single 800 mg
film.[56] The absolute bioavailability of fentanyl
from FBSFwas reported to be 71%, with ~51% of
the administered dose being absorbed through
the buccal mucosa.[56]
FBSF demonstrated low intra-individual phar-
macokinetic variability (coefficient of variation
7–10%) in a study of 24 healthy subjects, indicating
that it would be expected to have consistent effects
within a single individual in clinical practice.[78] By
contrast, FBSF demonstrated wide inter-individual
pharmacokinetic variability (23–39%), emphasizing
the need for careful titration when using rapid-onset
fentanyl formulations.[78]
3.3.2 Clinical Efficacy versus Placebo
The efficacy of FBSF has been assessed in
a multicentre, randomized, placebo-controlled,
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multiple crossover study of 80 opioid-tolerant
adult patients with cancer who experienced BTP.
Patients were eligible to enter the double-blind
crossover period if they were successfully titrated
within a 2-week period to an FBSF dose (200–
1200 mg) that provided suitable pain relief. Com-
pared with placebo, FBSF significantly reduced
pain intensity, as measured by summed PIDs over
30 minutes (SPID30; 38.1 vs 47.9; p= 0.004).[25] A
statistically significant (p< 0.05) improvement with
FBSF over placebo was reported for the SPID
from 15 minutes and persisted to the last time point
assessed in this study (60 minutes; p < 0.001).[25]
PID over time was statistically significantly greater
for FBSF versus placebo from 30 minutes until
the final assessment (p < 0.01). The proportion of
BTP episodes with clinically relevant improve-
ments in pain intensity is reported in table IV.
With FBSF, 30% of BTP episodes required rescue
medication versus 45% with placebo (p = 0.002).
The placebo response rate was noted to be
particularly high in this study. Although placebo
response rates are often high in pain studies
due to a weight of expectation on the part of the
patient, the particularly high rates here were at-
tributed to the innovative appearance of the buc-
cal film used to administer both FBSF and placebo.
It is thought that the perception of a novel de-
livery system may have raised patient expecta-
tions and sensitized them to even slight changes in
pain intensity.[25] However, it appears that other
ROOs with novel delivery systems (sublingual
fentanyl [SLF] and intranasal fentanyl spray
[INFS]) have lower placebo response rates.
To date no comparative studies have been
conducted of FBSF versus other opioids.
3.3.3 Safety and Tolerability
Similar to the other fentanyl formulations de-
scribed, FBSF has been reported to be well tol-
erated with an adverse-event profile typical of
opioid analgesics.[25]
3.3.4 Patient Satisfaction/Preference
Patient global satisfaction with FBSF was sig-
nificantly greater than with a placebo film using
the same BEMA technology in a double-blind,
randomized, crossover study of 80 patients with
cancer and BTP.[25] Satisfaction with FBSF and
placebo was reported to be excellent/good/very
good by 67.1% and 47.1% of patients, respect-
ively (no p-value reported), and overall satisfac-
tion mean scores were 2.0 and 1.5, respectively
(p < 0.001).[25]
3.4 Sublingual Fentanyl
SLF (Abstral) was developed by ProStrakan.
It was approved in the EU in 2008 for BTP in
opioid-tolerant adults with cancer and was ap-
proved in the US for the same indication in 2011.
The sublingual mucosa is highly vascularized and
has good permeability, allowing rapid absorption
of fentanyl.[27] SLF is a tablet comprising water-
soluble carrier particles that are coated with fen-
tanyl and amucoadhesive agent to hold the tablet
under the tongue. SLF is available in doses of
100–800 mg. The median dose used in a phase III
study of 60 patients with cancer and BTP was
600 mg (mean 550.8 mg) and a median of three
doses was taken each day.[26]
3.4.1 Pharmacokinetics
Summary pharmacokinetic data for SLF are
detailed in table III. Total fentanyl exposure with
SLF was proportional to the administered dose
(dose range 100–400 mg) in a pharmacokinetics
study comprising 11 patients with cancer.[57] Sys-
temic exposure and absorption increased in a linear
fashion with the doses assessed, and dose pro-
portionality was also reported for the Cmax of SLF
(100mg 0.24ng/mL, 200mg 0.41ng/mL and 400mg
0.91ng/mL). The tmax ranged from 40 to 60minutes
for the 100 mg and 400 mg doses, respectively.[57]
A study of 47 healthy opioid-naive Japanese
subjects examined the single- and repeat-dose
pharmacokinetics of SLF.[79] Subjects received
SLF 100, 200, 400 or 800 mg every 6 hours for a
total of 14 doses. Subjects administered repeated
doses of SLF 400 mg or 800 mg also received nal-
trexone to prevent opioid-mediated respiratory
depression. The plasma concentration of fentanyl
was dose proportional with the SLF dose. After a
single dose of SLF, median tmax ranged from 0.5
to 1.0 hours and after repeat dosing it ranged
from 0.5 to 2.0 hours.
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3.4.2 Clinical Efficacy versus Placebo
In a small crossover study of 27 adult patients
with locally advanced cancer and BTP, patients
received placebo and SLF 100, 200 or 400 mg for
one BTP episode in a random order separated by
a washout period of 1 day.[27] This study did not
use a preliminary titration phase to find the dose
with optimum efficacy and minimal adverse
events for each patient. SLF 400mg was associated
with the greatest improvements in PID when
compared with placebo and the other doses as-
sessed. SLF 400mg demonstrated an improvement
of 8.57mm (on a 100mm visual analogue scale)
compared with placebo over the treatment period
(p < 0.0001) and also gave a clinically (>20mm)
and statistically significant improvement in PID at
an earlier time point (15 minutes; p= 0.005) com-
pared with the other doses.[27] Use of rescue med-
ication was significantly less common with SLF
400mg compared with placebo (5 vs 15 patients;
p= 0.001). Despite the absence of a dose-titration
phase in this study, 22/23 patients (95%) identified
one or more doses of SLF that gave them clinically
relevant reductions in PID.[27] Compared with
placebo, a significantly greater number of patients
stated that SLF 400 mg was ‘‘excellent’’ when
prompted to give a global assessment of treat-
ment (three patients vs nine patients; p = 0.0146).
A multicentre, randomized, placebo-controlled,
phase III study conducted in the US assessed the
efficacy of SLF 100–800 mg in 66 patients with
cancer and BTP who had successfully completed
a dose-titration phase (table I).[26] The mean
SPID30 was significantly greater after adminis-
tration of SLF compared with placebo (49.5 vs
36.6; p = 0.0004). This difference was maintained
up to 1 hour after dosing (SPID60 143.0 vs 104.5;
p= 0.0002). Improvements in PID and pain relief
were also significantly greater with SLF compared
with placebo from 10 minutes and remained sig-
nificant throughout the 60-minute assessment
period (p £ 0.055 and p £ 0.049, respectively).
To date no published studies have compared
SLF with other opioids.
3.4.3 Safety and Tolerability
As with other fentanyl preparations, the most
common adverse events are typical of opioids –
constipation, nausea/vomiting and somnolence.[27]
Application-site abnormalities, for example, sto-
matitis (inflammation of the mucosa), have been
reported only rarely.[26]
3.4.4 Patient Satisfaction/Preference and
Quality of Life
In a phase III study that asked patients with
cancer pain and BTP to report their level of sa-
tisfaction with treatment using the Patient Global
Evaluation of Medication (where 1 = excellent
and 5 =poor), patients gave SLF an overall
satisfaction rating of 3.1 versus 3.6 for placebo
(p = 0.0006).[26] Furthermore, 29.7% of patients
reported that they were very satisfied with SLF at
the end of the study compared with 19.7% for
placebo.[26] In a large, open-label study of pa-
tients with chronic cancer pain and BTP who
were treated with SLF; 77% (71/92) of patients in
this 12-month maintenance phase study reported
that they were ‘‘very satisfied’’ or ‘‘satisfied’’ with
SLF treatment.[80]
Quality of life in patients receiving SLF was
assessed using the Brief Pain Inventory and the
Depression, Anxiety, and Positive Outlook Scale
in a 12-month open-label study of 85 patients
with chronic cancer pain and BTP.[80] Current
pain was significantly reduced at 6 months com-
pared with baseline (p = 0.01), while pain relief
(p< 0.05) and composite score for the interference
of pain (p < 0.001) were significantly improved at
6 months and study end. Life enjoyment was also
significantly improved at study end (p = 0.02) and
daily-functioning items did not deteriorate over
the study period. Depression scores improved
significantly over 6 months (p = 0.011) and other
mood items remained stable over the course of
the study.[80]
Sublingual fentanyl was subsequently exam-
ined in a phase IV, open-label study in 217 pa-
tients receiving fixed-schedule oral opioids for the
management of cancer-related pain.[81] Patients
reported statistically significant improvements in
daily functioning as measured by the modified
Brief Pain Inventory over a 28-day observation
period (mean combined score of 18 at the study
end vs 50.4 at enrolment; p< 0.0001). In addition,
there was a significant reduction in the percentage
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of patients reporting high levels of pain-related
disability (defined as a modified pain disability
score >40) at the end of the study compared with
enrolment (73.0% vs 12.1%). Furthermore, the
prevalence of anxiety and depression was sig-
nificantly reduced during the study period, as
measured by the Hamilton Anxiety and Depres-
sion Scale.
3.5 Intranasal Fentanyl Spray
The INFS Instanylwas developed byNycomed
and was approved in the EU in 2009 for BTP in
adults with cancer who are receiving and who are
tolerant of opioid analgesics for chronic cancer
pain. INFS is not available in the US. INFS is
available in doses of 50, 100 and 200 mg/spray.
Another intranasal fentanyl formulation with
pectin has also been developed and this is dis-
cussed in the next section.
3.5.1 Pharmacokinetics
The pharmacokinetics of INFS 50–200mg were
assessed in a study of 19 opioid-tolerant patients
with cancer and BTP (table III).[58] Median tmax
values were between 12 and 15 minutes for INFS
and the plasma concentration increased in a dose-
dependent manner, although Cmax increased in a
manner that was slightly less than proportional to
the dose. Importantly, this study demonstrated
that the pharmacokinetics of INFS in patients
with cancer and BTP were comparable to previous
results from studies in healthy volunteers.[58] In a
study conducted in patients with pain after oral
surgery, the bioavailability of INFS was 89% and
t½ was ~6.5 minutes.[59]
3.5.2 Clinical Efficacy versus Placebo
The efficacy of INFS 50–200 mg in opioid-
tolerant patients with cancer and BTP has been
assessed in a phase III, double-blind, random-
ized, placebo-controlled, crossover study con-
ducted across multiple centres in Europe.[28] A
total of 111 patients identified an effective dose of
INFS and entered the randomized stage of the
study. Compared with placebo, pooled mean PID
scores at 10, 20, 40 and 60 minutes were signif-
icantly higher (p< 0.001) for all INFS doses (PID10
scores 1.10 vs 2.36; p < 0.001). Fourteen percent
of patients required rescue medication while re-
ceiving INFS versus 45% of patients administered
placebo (p=not significant). The proportion of
patients who achieved a clinically meaningful re-
duction in pain (‡33% or ‡50% reduction) is
shown in table IV. Patients’ mean global im-
pression of treatment wasmeasured on a five-point
scale (where 0=poor and 5= excellent). The mean
global impression score for INFS (pooled doses)
was 1.88 versus 0.95 for placebo (p < 0.001); 75.4%
of patients reported that they perceived treatment
efficacy as good/very good/excellent for INFS
compared with 30.9% for placebo.[28]
3.5.3 Clinical Efficacy versus Other Opioids
An open-label, randomized, multicentre study
conducted in European countries compared INFS
(50–200mg)withOTFC (200–1600mg) in 139 opioid-
tolerant patients with cancer and BTP who had
successfully identified effective analgesia in the
preliminary titration phase.[29] Meaningful pain
relief in this study was defined by each patient in-
dividually with no input from study investigators
or healthcare professionals; onset of meaningful
pain relief was monitored with a stopwatch from
the administration of the first fentanyl dose taken
during a single BTP episode. Patients reported that
meaningful pain relief was achieved in a median
time of 11 minutes with INFS compared with
16 minutes for OTFC.Moreover, 66% of patients
reported experiencing a faster onset of meaning-
ful pain relief with INFSversusOTFC (p< 0.001).[29]
Compared with OTFC, adjusted mean PID was
statistically significantly greater for INFS from
10 minutes (p < 0.001) through to the final as-
sessment at 60 minutes (p < 0.01). SPID0–15 and
SPID0–60 scores were also significantly greater for
INFS versus OTFC (treatment differences of 0.82
and 0.70 for the two assessments, respectively;
both p< 0.001).[29] The proportions of patients
achieving ‡33% and ‡50% reductions in pain in-
tensity at 5 and 10 minutes are shown in table IV.
Rescue medication for BTP was used by a
greater proportion of patients receiving INFS
compared with patients taking OTFC (7.8% vs
4.9%). This difference was ascribed to the study
protocol requirement for patients to wait longer
before rescue medication could be used after
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taking an OTFC dose (45–60 minutes) compared
with 20 minutes after the first dose of INFS.[29]
This requirement was based on the longer time
for administration of the OTFC lozenge. Patients
scored their general impression of treatment on a
five-point scale (where 0 =poor and 4 = excellent)
60 minutes after administration.[29] The treat-
ment difference for general impression between
the two formulations was 0.2 in favour of INFS
(p < 0.001). It should be noted that the open-label
design of this study may have inadvertently fa-
voured INFS, as patients may expect greater
benefits from newer formulations and may have
had previous experience with the OTFC lozenge.
Although double-blinding in this study would
have involved the use of placebo sprays and loz-
enges at the same time as the active dose, this may
have assisted in avoiding bias in patients’ percep-
tions of efficacy. In addition to the open-label en-
rolment protocol, the fact that only 86 patients
completed both treatments and the use of onset of
‘‘meaningful’’ pain relief as the primary outcome
measure make it difficult to draw firm conclusions
regarding the superior efficacy of IFNSoverOTFC.
INFS has been indirectly compared with
OTFC, FBT and oral morphine in a statistical
comparison of the results of studies identified
during a systematic review.[82] This study eval-
uated six published reports and revealed that the
fentanyl formulations gave greater pain relief at
earlier time points than oral morphine. Morphine
did not provide better analgesia than placebo
until 45 minutes after dosing, meaning that
patients with BTP are unlikely to obtain pain
relief sufficiently rapidly with this medication.
Reductions in pain intensity with INFS on an
11-point numeric rating scale were clinically
meaningful (improvement of ‡2 points) from
30 minutes. Treatment comparison revealed that
on an 11-point numeric rating scale, differences
in PID15 with INFS were 1.2, 1.3 and 1.7 points
compared with FBT, OTFC and oral morphine,
respectively, although these improvements did
not reach statistical significance.[82]
3.5.4 Safety and Tolerability
Aside from the opioid-related adverse events
that are usually reported in fentanyl safety anal-
yses, INFS was also associated with dysgeusia, a
distortion of taste, and balance problems such as
dizziness and vertigo.[28] Ulcers of the nasal mu-
cosa have also been reported with IFNS.[29]
3.5.5 Patient Satisfaction/Preference
In a study comparing the analgesic effects of
INFS with those of OTFC, 84 patients with
cancer and BTP were questioned on their pref-
erences regarding the two formulations. INFS
was favoured by 77.4% of patients compared
with 22.6% who preferred the buccal formulation
(p< 0.001); 90.1% of patients found INFS easy/very
easy to use compared with 39.8% for OTFC.[29]
3.6 Fentanyl Pectin Nasal Spray
The fentanyl pectin nasal spray (FPNS)
[PecFent (EU trade name), Lazanda (US trade
name)] was developed by Archimedes Pharma. It
was approved in the EU in 2010 and in the US in
2011 for BTP in adults with cancer who are receiv-
ing and who are tolerant of opioid analgesics for
chronic cancer pain. In January 2011, the Scottish
Medicines Consortium accepted the use of FPNS
for patients with cancer experiencing BTP as an al-
ternative to other fentanyl formulations or for those
who cannot take short-acting opioids. FPNS is
available in doses of 100 and 400mg/spray.
The addition of pectin in FPNS promotes the
formation of a gel on contact with calcium cations
on the nasal mucosa, prolonging the residence
time of fentanyl at the mucosa and giving a
rounded pharmacokinetic profile compared with
the sharp profile of non-gelling sprays.[60,83] This
pectin-based drug delivery system is referred to as
PecSys.[83] The high, early Cmax of the non-gelling
sprays is reported to be indicative of a wide co-
efficient of variation and less predictable efficacy
and tolerability.[60] FPNS has demonstrated a
slower decline in plasma fentanyl levels compared
with non-gelling nasal sprays, suggesting that
FPNS provides comparably extended analgesia
versus non-gelling intranasal formulations.[60]
3.6.1 Pharmacokinetics
Summary pharmacokinetic data for FPNS are
detailed in table III. In a pharmacokinetics study
of fentanyl intranasal spray preparations that
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form gelling matrices on contact with the nasal
mucosa, FPNS was compared with two other
novel intranasal preparations and OTFC. The
study was conducted in 18 healthy volunteers and
comprised a randomized, single-dose, open-label,
four-way crossover design.[84] In this study, the
tmax for FPNS was ~20 minutes and the Cmax was
337 pg/mL. The other gelling formulations eval-
uated in this study had a higher Cmax and a shorter
tmax than FPNS, but it was posited that such
pharmacokinetics were likely to lead to increased
rates of adverse events.[84] Indeed, the two non-
pectin gel formulations did have poorer tolerability
profiles in this study, leading to FPNS being pur-
sued as a novel intranasal spray formulation.[84]
The pharmacokinetics of FPNS (100, 200, 400
and 800 mg) and OTFC have been compared di-
rectly in a single-dose, open-label, five-period,
crossover study of 16 opioid-naive healthy sub-
jects.[60] FPNS demonstrated a dose-independent
tmax that was significantly reduced compared
with OTFC (15–21 minutes vs 90 minutes;
p< 0.01). The Cmax of FPNS increased in a dose-
proportional manner (352 pg/mL and 2844 pg/mL
for the 100 mg and 800 mg doses, respectively) and
was significantly higher for FPNS versus OTFC
(p < 0.001).
3.6.2 Clinical Efficacy versus Placebo
In a randomized, placebo-controlled study of
83 opioid-tolerant patients with cancer and BTP,
clinically relevant reductions of ‡2 points in ab-
solute pain intensity (measured on an 11-point
numeric scale) were observed within 10 minutes
in 33% of BTP episodes treated with FPNS versus
25% of patients given placebo (p < 0.05). Clini-
cally meaningful improvements in pain relief were
also recorded at 10 minutes with FPNS (33% vs
24% for placebo; p < 0.01).[31] Rescue medication
use was required within 60 minutes in 9% of BTP
episodes treated with FPNS compared with 20%
of episodes treated with placebo (p < 0.001).[31] In
the same study, FPNS demonstrated significantly
greater mean SPID30 scores compared with pla-
cebo (6.57 vs 4.45; p < 0.0001).[30] Compared with
placebo, a significantly greater proportion of pa-
tients treated with FPNS reported onset of an-
algesia (‡1 point reduction in pain intensity score)
from 10 minutes (38.4% vs 56.2%; p< 0.01). The
reduction in pain intensity became clinically
meaningful (‡2 point reduction) for 49% of
FPNS-treated patients at 15 minutes and 63% at
30 minutes.[30] Clinically meaningful pain relief
was reported by a significantly higher proportion
of patients receiving FPNS versus placebo from
10 minutes (32.9 vs 24.5; p = 0.01). Rescue med-
ication within 60 minutes was required during
9.4% of BTP episodes treated with FPNS com-
pared with 20.0% of episodes treated with placebo
(p < 0.001).[30]
In a long-term (16-week), open-label study of
~350 patients with cancer pain and BTP, rescue
medication was required for only 6% of BTP epi-
sodes treated with FPNS.[85] Moreover, the FPNS
dose was stable with long-term use (4 months)
and less than 10% of patients required an increase
in initial dose.[85]
3.6.3 Clinical Efficacy versus Other Opioids
FPNS has recently been compared with oral
immediate-release morphine sulphate in a double-
blind, multiple-crossover study of 110 patients
with chronic cancer pain and BTP.[32] Compared
with morphine sulphate, clinically meaningful
improvements in pain intensity (‡2-point reduc-
tion on an 11-point numeric scale) were reported
for a significantly higher proportion of FPNS-
treated BTP episodes from 10 minutes (45.4% vs
52.4%; p < 0.05). In addition, clinically mean-
ingful pain relief (score ‡2 on a 5-point numeric
scale) was reported during significantly fewer
BTP episodes treated with morphine sulphate
than FPNS from 15 minutes (53.4% vs 60.2%;
p < 0.05).[32] From 30 minutes, the differences
between FPNS and morphine sulphate in terms
of changes in pain parameters were static or be-
gan to diminish.[32] Rescue medication was required
within 60 minutes in 3.0% and 3.8% of FPNS-
and morphine sulphate-treated BTP episodes,
respectively (p = 0.57).[32]
3.6.4 Safety and Tolerability
Typical opioid treatment-related adverse events
were reported by approximately one-quarter
of patients in a 16-week open-label study of
FPNS.[85] One death (out of a total of 80 deaths
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during the study) was considered to be possibly
related to the use of FPNS. This patient died after
peritonitis-complicated bowel perforation, pos-
sibly due to opioid-induced constipation.[85] Ap-
proximately half of the patients receiving FPNS
experienced treatment-emergent adverse events in
a placebo-controlled, multiple-crossover study.[30]
One event of noncardiac chest pain was judged to
be possibly related to the study drug. Mild to
moderate nasal tolerability events were reported
in ~10 patients in this study (n = 113).[30] Nasal
adverse events reported in a study (n = 89) com-
paring FPNS with immediate-release morphine
sulphate included mild obstruction (2.2%) and
mild nasal discharge (4.5%).[32]
3.6.5 Patient Satisfaction/Preference
In a study of 16 healthy volunteers adminis-
tered FPNS as part of a pharmacokinetics anal-
ysis, five subjects rated nasal dosing with fentanyl
to be slightly or moderately inconvenient.[60]
By contrast, in a larger randomized, placebo-
controlled, double-blind study in patients with
cancer and BTP, satisfaction with the ‘‘conve-
nience of use’’ of intranasal fentanyl spray was
reported by 70% of patients and satisfaction with
‘‘ease of use’’ was reported by 69% of patients.[31]
Compared with oral immediate-release mor-
phine sulphate, patients reported (on a scale of
1–4) that they were significantly more satisfied
with FPNS: overall (2.73 vs 3.01 at 60 minutes;
p£ 0.01); in terms of speed of pain relief (2.72 vs
3.01 at 60 minutes; p £ 0.01); and in terms of re-
liability (2.74 vs 3.03 at 60 minutes; p £ 0.01).[32]
These higher ratings of patient satisfaction with
FPNS versus morphine sulphate were reflected in
the high proportion (70%) of patients who chose
to continue treatment with FPNS in an open-
label extension.[32]
4. Future Formulations
Of the products currently in development for
BTP, Taifun – intrapulmonary fentanyl admin-
istered with an inhaler – is closest to obtaining
approval. A phase II, randomized, double-blind,
placebo-controlled study of intrapulmonary fen-
tanyl 100, 200 and 400 mg in 122 opioid-tolerant
patients with cancer and BTP, reported that the
active treatment resulted in significant pain relief
within ~10 minutes and significantly better SPID
scores.[86] A multicentre, phase III safety study of
intrapulmonary fentanyl was completed in 2010
and the full results of this and the phase II efficacy
study are awaited. Other opioid and non-opioid
formulations in development for BTP include
subcutaneous hydromorphone, sublingual metha-
done, and intranasal morphine, ketamine and
dexmedetomidine.[13]
5. Discussion
The studies discussed in this review indicate
that, with the exception of the findings from a
single open-label study, with the limitations in-
herent of non-blinded analysis, the efficacy and
safety profiles of the ROOs for cancer-related
BTP are comparable to each other, although
OTFC has markedly lower bioavailability. Un-
fortunately, there are no published double-blind,
head-to-head studies from which to draw further
conclusions on the clinical differences between
and patient preferences for the currently avail-
able formulations.
A recent economic evaluation of INFS com-
pared with FBT and OTFC used data from
Sweden to model the potential cost:benefit ratios
of these formulations.[87] This model revealed that
over a time horizon of 180 days INFS dominated
OTFC (i.e. conferred benefits in terms of quality-
adjusted life-years [QALYs] and cost compared
with the buccal formulation) and was cost effec-
tive compared with FBT (had an incremental
cost-effectiveness ratio of 12 203 Euros/QALY
gained).[87] The cost of treatments is an important
consideration when making management deci-
sions, particularly for chronic conditions. Addi-
tional studies regarding the health economics of
treatment for BTP would be welcome, partic-
ularly with longer time horizons and across more
countries.
There are a number of factors to take into ac-
count when considering whether the results of the
studies reviewed here are applicable to the wider
clinical population. For example, the patient pop-
ulations in these studies were ‘‘enriched’’ or
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‘‘preselected for response’’ due to very specific
enrolment criteria and a need for titration to an
effective fentanyl dose.[25] Without careful titra-
tion and patient selection, it is unlikely that clin-
icians will observe the same high levels of pain
relief in their own practices. However, such pa-
tient selection and titration with fentanyl is vital
to avoid safety risks. Instances of serious illness
and death have occurred in opioid non-tolerant
patients treated with fentanyl, patients who have
misunderstood their dosing schedule and patients
who have substituted one fentanyl formulation
with another.[40] Fentanyl formulations cannot
be used interchangeably due to their different
pharmacokinetic profiles.
Consideration of the pharmacokinetic pro-
files of fentanyl formulations is fundamental in
choosing the most appropriate treatment for each
patient as they can indicate the likely onset of
action and the potency of the effect of the medica-
tion (Cmax and bioavailability). Most pharmaco-
kinetic studies of fentanyl have been performed in
healthy volunteers, but it should be remembered
that patients requiring relief fromBTPmay be using
concomitant medications or may have hepatic
impairment and therefore the pharmacokinetics
of fentanyl may differ substantially in clinical prac-
tice.[67] To date, the pharmacokinetics of INFS and
SLF have been reported in patients with cancer and
BTP; in these studies, INFS and SLF demonstrated
pharmacokinetics that were comparable between
patients and healthy volunteers.[57,58]
Patients with BTP frequently have a high
burden of morbidity due to both their disease and
to treatments for the disease and for chronic pain.
These aspects have, to date, made it difficult for
investigators to assess the safety profile of ROOs –
differentiating between treatment-emergent ad-
verse events and underlying morbidity is not
simple. In addition, the usefulness of any ‘‘back-
ground’’ assessment of the safety of ROOs in
healthy subjects during pharmacokinetics studies
is limited by the use of naltrexone to stop subjects
from experiencing opioid-associated effects, such
as respiratory depression. There is, therefore, a
possible gap in our knowledge regarding the true
safety and tolerability profiles of ROOs in pa-
tients with BTP.
The transmucosal and intranasal routes have
been a focus for drug development in patients
with chronic pain and BTP due to ease of use and
the absorption and bioavailability profiles over
time, which closely match the dynamics of BTP.
A recent Delphi survey of 33 Danish general
practitioners assessed which characteristics of
INFS and OTFC led to clinicians prescribing/not
prescribing these formulations.[88] Reasons for
prescribing OTFC included the possibility of self-
administration and its utility as a medication for
frequent dosing in patients with BTP; reasons for
choosing an alternative to OTFC included pa-
tient confusion, high cost and the occurrence of
dry mouth and nausea.[88] Furthermore, other
studies have reported that some patients find the
appearance of the OTFC lozenge embarrassing
as it makes them look childish.[7,35] Results of the
Delphi study indicated that benefits associated
with INFS were the potential for it to be ad-
ministered by family members (reducing direct
patient treatment burden) and being suitable for
use in patients with dry mouth. Reported ratio-
nales for not prescribing INFS were application
side effects (such as nasal irritation) and issues
with the nasal mucosa, such as colds and influ-
enza or disease pathology.[88]
Studies that discuss the disadvantages and
advantages of different routes of administration
for BTP in general,[35] or with fentanyl specifi-
cally,[88] serve to highlight the potential for indi-
vidualizing treatments for BTP. Because the use
of BTP treatments is influenced by patient-centric
factors, such as underlying disease character-
istics, patient preferences and ease of adminis-
tration, the available formulations for BTP can
be prescribed according to the needs of the pa-
tient and should improve the clinical response as
a result. There is potential for other administra-
tion routes to be used for the treatment of BTP,
and it is likely that future research will focus on
expanding the options available to patients by
exploring these alternatives and also on optimizing
the bioavailability of fentanyl through currently
available modalities. ROOs are recommended for
the treatment of most BTP episodes in opioid-
tolerant patients with cancer, particularly those
episodes that are unpredictable, of an extremely
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intense nature or very short duration, or have a
rapid steep climb to peak intensity.
Conclusion
The last 5 years have seen the introduction of a
range of fentanyl-based ROOs with different ad-
ministration routes for the management of BTP
in opioid-tolerant patients with cancer. Given the
absence of data from double-blind, head-to-head
trials, it is not currently possible to conclude that
any formulation is superior to another. Based on
available data, mainly from placebo-controlled
trials, the current formulations appear to be com-
parable in terms of efficacy and safety. It is likely
that factors such as disease characteristics, patients’
preference and ease of administration will continue
to be key determinants in deciding the most ap-
propriate formulation for individual patients.
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